Artwork

Content provided by MDedge and Medscape Professional Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MDedge and Medscape Professional Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Biologics for psoriasis during the COVID-19 pandemic

24:25
 
Distribuie
 

Manage episode 282258382 series 2356616
Content provided by MDedge and Medscape Professional Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MDedge and Medscape Professional Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In the news:

Baseline body surface area may drive optimal baricitinib responses

Avoiding atopic dermatitis triggers easier said than done

* * * * * * * * *

Psoriasis patients often have additional comorbidities that put them at higher risk for developing COVID-19. In this episode, Candrice R. Heath, MD (@DrCandriceHeath), talks to Mark G. Lebwohl, MD, about the benefits of continuing biologic therapies for psoriasis during the COVID-19 pandemic. They discuss findings from registry data in Italy and New York City and how the data have impacted the latest guidelines for treatment. “The [National Psoriasis Foundation COVID-19 Task Force] has come out with a recommendation that strongly encourages patients on biologics to take [the COVID-19] vaccination and to not interrupt your biologic therapy,” Dr. Lebwohl explains. They also discuss how dermatologists can counsel patients about the safety of biologics so they feel comfortable continuing treatment during the pandemic.

* * *

Hosts: Nick Andrews; Candrice R. Heath, MD (Temple University Hospital, Philadelphia)

Guests: Mark G. Lebwohl, MD (Icahn School of Medicine at Mount Sinai, New York)

Disclosures: Dr. Heath reports no conflict of interest. Dr. Lebwohl is an employee of Mount Sinai and has received research funds and consulted with numerous pharmaceutical companies.

Show notes by: Alicia Sonners, Melissa Sears

* * *

You can find more of our podcasts at http://www.mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgeDerm

  continue reading

106 episoade

Artwork
iconDistribuie
 
Manage episode 282258382 series 2356616
Content provided by MDedge and Medscape Professional Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MDedge and Medscape Professional Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In the news:

Baseline body surface area may drive optimal baricitinib responses

Avoiding atopic dermatitis triggers easier said than done

* * * * * * * * *

Psoriasis patients often have additional comorbidities that put them at higher risk for developing COVID-19. In this episode, Candrice R. Heath, MD (@DrCandriceHeath), talks to Mark G. Lebwohl, MD, about the benefits of continuing biologic therapies for psoriasis during the COVID-19 pandemic. They discuss findings from registry data in Italy and New York City and how the data have impacted the latest guidelines for treatment. “The [National Psoriasis Foundation COVID-19 Task Force] has come out with a recommendation that strongly encourages patients on biologics to take [the COVID-19] vaccination and to not interrupt your biologic therapy,” Dr. Lebwohl explains. They also discuss how dermatologists can counsel patients about the safety of biologics so they feel comfortable continuing treatment during the pandemic.

* * *

Hosts: Nick Andrews; Candrice R. Heath, MD (Temple University Hospital, Philadelphia)

Guests: Mark G. Lebwohl, MD (Icahn School of Medicine at Mount Sinai, New York)

Disclosures: Dr. Heath reports no conflict of interest. Dr. Lebwohl is an employee of Mount Sinai and has received research funds and consulted with numerous pharmaceutical companies.

Show notes by: Alicia Sonners, Melissa Sears

* * *

You can find more of our podcasts at http://www.mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgeDerm

  continue reading

106 episoade

Tous les épisodes

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință